Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:8231) expected to record a substantial increase in profits for the year ended 31 December 2011 as compared to the profits in the year 2010. Such increase in profits is mainly attributable to the Strategic Cooperation Agreement for innovative pharmaceuticals research and development entered into between the Company and Shanghai Pharmaceuticals, pursuant to which Shanghai Pharmaceutical shared part of the research expenses of some of the Group’s project).